TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11526203

Group type: EXPERIMENTAL
Intervention: Malaria DNA vaccine administered by needle i.m. or needleless jet injection
Number of subjects: 14
Study: 9817534

Group type: EXPERIMENTAL
Intervention: Long-term treatments for multiple sclerosis
Number of subjects: 0
Study: 7544030

Group type: EXPERIMENTAL
Intervention: Paclitaxel (up to 250 mg/m2) followed by Carboplatin (up to 400 mg/m2)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Carboplatin (300 mg/m2) with Paclitaxel (200 mg/m2)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Paclitaxel (250 mg/m2) with Carboplatin (350 mg/m2)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Paclitaxel (above 200 mg/m2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Paclitaxel and Carboplatin (both sequences)
Number of subjects: 62
Study: 2652281

Group type: EXPERIMENTAL
Intervention: Six-month therapy with a fixed combination of 120 mg rifampicin, 50 mg isoniazid, and 300 mg pyrazinamide (Rifater)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Present Swiss standard therapy (Daily rifampicin, isoniazid, and ethambutol for 2 months followed by rifampicin and isoniazid for 7 months)
Number of subjects: 93
Study: 788758

Group type: EXPERIMENTAL
Intervention: Pindolol administered once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol administered once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blocking drugs (general)
Number of subjects: 0
Study: 30863471

Group type: EXPERIMENTAL
Intervention: USG bilateral subcostal TAP block with 0.3 ml/kg bupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: USG bilateral QL block with 0.3 ml/kg bupivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: USG bilateral subcostal TAP block
Number of subjects: 120

Group type: COMPARATOR
Intervention: USG bilateral QL block
Number of subjects: 120
Study: 28025574

Group type: EXPERIMENTAL
Intervention: Preoperative Physical Activity Intervention (PAI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 75
Study: 26228178

Group type: EXPERIMENTAL
Intervention: 10% w/v CPP‐ACP paste
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 103
Study: 23531425

Group type: EXPERIMENTAL
Intervention: Second-look endoscopy (SLE)
Number of subjects: 182

Group type: COMPARATOR
Intervention: No second-look endoscopy (no-SLE)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Both groups (SLE and no-SLE)
Number of subjects: 182
Study: 21390582

Group type: EXPERIMENTAL
Intervention: High dosage of Astragalus granule (7.5 g)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Moderate dosage of Astragalus granule (4.5 g)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low dosage of Astragalus granule (2.25 g)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Perindopril (4 mg)
Number of subjects: 90
Study: 19721214

Group type: EXPERIMENTAL
Intervention: Active hip abduction test (examiner scored)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Active hip abduction test (self-rated)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Prolonged standing protocol
Number of subjects: 43
Study: 17443000

Group type: EXPERIMENTAL
Intervention: Interleukin-2-based immunotherapy
Number of subjects: 363
Study: 15013613

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11440296

Group type: EXPERIMENTAL
Intervention: Postal and telephone reminders during the first 2 months of pravastatin treatment
Number of subjects: 12800

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12800
Study: 9754889

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg in D5W
Number of subjects: 6

Group type: COMPARATOR
Intervention: D5W alone
Number of subjects: 6
Study: 8058228

Group type: EXPERIMENTAL
Intervention: Metronidazole (400 mg twice daily) for two 2-day courses, first at 24 weeks' gestation and second at 29 weeks if G vaginalis was present.
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Metronidazole (after second course)
Number of subjects: 196
Study: 2702513

Group type: EXPERIMENTAL
Intervention: 200 micrograms of nasally applied budesonide twice daily
Number of subjects: 98

Group type: COMPARATOR
Intervention: 250 micrograms of orally administered budesonide twice daily
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 769572

Group type: EXPERIMENTAL
Intervention: Pyrimethamine 75 mg and sulfadoxine 1,500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyrimethamine 50 mg and diformyldapsone 800 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pyrimethamine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulfadoxine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pyrimethamine-diformyldapsone
Number of subjects: 0
Study: 31461400

Group type: EXPERIMENTAL
Intervention: Active continuous diffusion of oxygen (CDO)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Active continuous diffusion of oxygen (CDO) with frequent debridement
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo device with frequent debridement
Number of subjects: 146
Study: 26941340

Group type: EXPERIMENTAL
Intervention: VVIR 70-130/min biventricular pacing
Number of subjects: 60

Group type: COMPARATOR
Intervention: VVI 70/min biventricular pacing
Number of subjects: 60
Study: 26073497

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (3 hours)
Number of subjects: 98
Study: 23174256

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate
Number of subjects: 280

Group type: COMPARATOR
Intervention: Plasmakinetic resection of the prostate
Number of subjects: 280
Study: 16847815

Group type: EXPERIMENTAL
Intervention: Bicalutamide plus tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bicalutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bicalutamide plus anastrozole
Number of subjects: 0
Study: 12900688

Group type: EXPERIMENTAL
Intervention: CPX/D
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CPX/DDelta
Number of subjects: 12

Group type: COMPARATOR
Intervention: FU system
Number of subjects: 12
Study: 10481867

Group type: EXPERIMENTAL
Intervention: Intron-A (interferon-alpha 2b) at standard doses (5 IU/m2/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-dose interferon-alpha-2b (reaferon and intron-A, 1-3 IU/m2/day) in combination with chemotherapy
Number of subjects: 42
Study: 9086958

Group type: EXPERIMENTAL
Intervention: Supportive intervention to reduce postnatal depression
Number of subjects: 249

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: MASQ vulnerable group
Number of subjects: 249

Group type: COMPARATOR
Intervention: MASQ less vulnerable group
Number of subjects: 249
Study: 1713091

Group type: EXPERIMENTAL
Intervention: Zinc therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 6880922

Group type: EXPERIMENTAL
Intervention: Television with drinking depicted
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Television without drinking
Number of subjects: 0

Group type: COMPARATOR
Intervention: No television control condition
Number of subjects: 0
Study: 31796528

Group type: EXPERIMENTAL
Intervention: Higher plasma α‐linolenic acid (ALA) in men
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Higher plasma arachidonic acid in women
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Higher plasma docosahexaenoic acid (DHA) in men and women combined
Number of subjects: 275
Study: 30685759

Group type: EXPERIMENTAL
Intervention: Maternal hematological parameters (specifically platelet count)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placental volume
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Umbilical arterial lumen cross-sectional area
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal hematological parameters
Number of subjects: 0
Study: 28291023

Group type: EXPERIMENTAL
Intervention: 100 Hz NMES protocol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60 Hz NMES protocol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 Hz NMES protocol
Number of subjects: 10
Study: 25150812

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waiting list group (Control)
Number of subjects: 24
Study: 23448393

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery by MDLAP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 12
Study: 21314329

Group type: EXPERIMENTAL
Intervention: Curcumin administration
Number of subjects: 0
Study: 19824094

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NaHCO3 infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extracellular fluid volume expansion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemofiltration/hemodialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type of radiocontrast media
Number of subjects: 0
Study: 16414263

Group type: EXPERIMENTAL
Intervention: Gait Walker (DeRoyal Industries, Inc.)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Equalizer (Royce Medical Co.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Laboratory shoes (Noveto, Adidas)
Number of subjects: 11
Study: 14604059

Group type: EXPERIMENTAL
Intervention: Centella asiatica and Punica granatum extracts (medicated chips)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unmedicated chips (placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both test and control groups
Number of subjects: 20
Study: 10783014

Group type: EXPERIMENTAL
Intervention: aP vaccine
Number of subjects: 1207

Group type: COMPARATOR
Intervention: TdaP‐IPV vaccine
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Td‐IPV
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Second dose of acellular pertussis vaccine
Number of subjects: 1207
Study: 8854782

Group type: EXPERIMENTAL
Intervention: Arterial infusion (AI) chemotherapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Systemic therapy (ST)
Number of subjects: 41
Study: 1616115

Group type: EXPERIMENTAL
Intervention: Droperidol (0.075 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.15 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: NaCl (0.1 ml/kg)
Number of subjects: 100
Study: 6380362

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 219

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 219
Study: 30368898

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention programme consisting of four group sessions, 84 SMS or voice messages, and review phone calls over the first year; additional individual sessions for those needing intensification.
Number of subjects: 1414

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1414
Study: 29767728

Group type: EXPERIMENTAL
Intervention: 150 mg andecaliximab every 2 weeks (Q2W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 mg andecaliximab weekly (QW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 mg andecaliximab Q2W and QW
Number of subjects: 0

Group type: COMPARATOR
Intervention: 150 mg andecaliximab and placebo
Number of subjects: 0
Study: 27524768

Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 25252254

Group type: EXPERIMENTAL
Intervention: Close-up White Now
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral-B 3D White
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Colgate Luminous White
Number of subjects: 60

Group type: COMPARATOR
Intervention: Colgate Total 12
Number of subjects: 60
Study: 22363361

Group type: EXPERIMENTAL
Intervention: Midazolam/Ketamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam/Promethazine
Number of subjects: 0
Study: 20164411

Group type: EXPERIMENTAL
Intervention: Daily reinforcement of speed (DRS) after a single, daily 10-m walk
Number of subjects: 179

Group type: COMPARATOR
Intervention: No reinforcement of speed (NRS) after the walk
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Daily reinforcement of speed (DRS)
Number of subjects: 179

Group type: COMPARATOR
Intervention: No reinforcement of speed (NRS)
Number of subjects: 179
Study: 17379123

Group type: EXPERIMENTAL
Intervention: IV ketamine 0.5 mg/kg in 2 mL saline before surgery, followed by continuous IV infusion of ketamine at 6 micro/(kg/min)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Saline infusion (10 mL/h) until bleeding control, with 0.8 mg/kg ketamine during bleeding control in 2 mL saline
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline only
Number of subjects: 90
Study: 15747897

Group type: EXPERIMENTAL
Intervention: Adjunctive subantimicrobial dose doxycycline (SDD; 20 mg doxycycline twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) + placebo
Number of subjects: 24
Study: 11874994

Group type: EXPERIMENTAL
Intervention: PPI + 1 day of H2RA (ranitidine 300 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: PPI twice daily alone
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PPI twice daily + H2RA after 1 week
Number of subjects: 43
Study: 10518812

Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study: 7616418

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.025 microgram/kg/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.1 microgram/kg/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alfentanil (0.5 microgram/kg/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naloxone (6 micrograms/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (instead of naloxone)
Number of subjects: 12
Study: 2264621

Group type: EXPERIMENTAL
Intervention: Kallikrein (600 units orally per day) for 3 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 65
Study: 538213

Group type: EXPERIMENTAL
Intervention: Amitriptyline (N = 30)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (N = 17)
Number of subjects: 47
Study: 30142133

Group type: EXPERIMENTAL
Intervention: Ujjayi breathing technique
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bhastrika breathing technique
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Kapalabhati breathing technique
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal breathing (control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Isokinetic power measured at 60, 180, and 300°·s
Number of subjects: 32
Study: 30653531

Group type: EXPERIMENTAL
Intervention: Health‐literate action plan (guided implementation intention)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Standard action plan (self‐guided implementation intention)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Education (healthy snacking fact‐sheet)
Number of subjects: 440
Study: 28122105

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg orally, once daily) for 10 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Acetylcysteine with amoxicillin‐clavulanic acid, pseudoephedrine, and intranasal normal saline
Number of subjects: 39
Study: 24256097

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 11
Study: 22889929

Group type: EXPERIMENTAL
Intervention: Machine-supported gait training with the Lokomat
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Physiotherapy with visual feedback components (PT-vf)
Number of subjects: 25
Study: 21056671

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MPA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: NONMEM
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: NPAG
Number of subjects: 34
Study: 19447835

Group type: EXPERIMENTAL
Intervention: Spontaneous reperfusion (SR) in non-diabetic patients
Number of subjects: 4944

Group type: EXPERIMENTAL
Intervention: Spontaneous reperfusion (SR) in diabetic patients
Number of subjects: 4944

Group type: EXPERIMENTAL
Intervention: Non-diabetic patients with normoglycaemia
Number of subjects: 4944

Group type: EXPERIMENTAL
Intervention: Diabetic patients with normoglycaemia
Number of subjects: 4944
Study: 17097398

Group type: EXPERIMENTAL
Intervention: Topical retapamulin ointment 1% (twice daily for 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral cephalexin (500 mg twice daily for 10 days)
Number of subjects: 0
Study: 14984435

Group type: EXPERIMENTAL
Intervention: TGZ 600 mg daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TGZ 200 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11318049

Group type: EXPERIMENTAL
Intervention: Event-related potentials (ERPs) recorded during a discrimination task with cued target location and response.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cued target location and response expectancy.
Number of subjects: 0
Study: 9524792

Group type: EXPERIMENTAL
Intervention: Rifaximin (100 mg every six hours for an average of four days)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Paromomycin (125 mg every six hours for an average of four days)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 49
Study: 8292061

Group type: EXPERIMENTAL
Intervention: Eryfer 100 (100 mg Fe++)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Eryfer (50 mg Fe++)
Number of subjects: 16
Study: 3557739

Group type: EXPERIMENTAL
Intervention: Brand A of furosemide
Number of subjects: 7

Group type: COMPARATOR
Intervention: Brand B of furosemide
Number of subjects: 7
Study: 29371381

Group type: EXPERIMENTAL
Intervention: Inhaled diesel exhaust (DE) combined with allergen exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled diesel exhaust (DE) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allergen exposure alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 0
Study: 26551230

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Support Group
Number of subjects: 38
Study: 24560541

Group type: EXPERIMENTAL
Intervention: Vaccine (Merck Ad5 gag/pol/nef subtype B HIV‐1 preventive vaccine)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 801
Study: 22563210

Group type: EXPERIMENTAL
Intervention: Ertapenem, 1 g once daily
Number of subjects: 271

Group type: COMPARATOR
Intervention: Ceftriaxone, 2 g once daily
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 271

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Ertapenem and Ceftriaxone
Number of subjects: 271
Study: 20925543

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (5571 patients)
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Standard glucose control (5569 patients)
Number of subjects: 11140
Study: 18179827

Group type: EXPERIMENTAL
Intervention: 1.0% ropivacaine hydrochloride soaked swabs
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline-soaked swabs
Number of subjects: 41
Study: 16170477

Group type: EXPERIMENTAL
Intervention: Polanight (PN)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Opalescence (OP)
Number of subjects: 58
Study: 12455806

Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin 1 gm every 8 hours for 3 days, then oral cephalexin 500 mg every 6 hours for 4 days
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin followed by oral cephalexin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 10348767

Group type: EXPERIMENTAL
Intervention: Azithromycin 1 g orally once on the first day, followed by 500 mg orally once daily for the next 6 days
Number of subjects: 123

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg orally twice daily for 7 days
Number of subjects: 123
Study: 7589012

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) 20 mg i.v. bolus
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Insulin (0.15 IU kg-1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 31
Study: 2031508

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU), 1,200 mg/m2 i.v. infusion over 2 h
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), 200 mg/m2 i.v. (push injection), followed 20 h later by 5-FU, 1,200 mg/m2 i.v. infusion over 2 h, plus calcium leucovorin (LV), 25 mg i.m. every 6 h for eight doses beginning 24 h after MTX administration
Number of subjects: 125

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) followed by 5-FU and LV
Number of subjects: 125
Study: 7146823

Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium‐heparin (5000 IU every 12 h for at least 2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vitamin K (for 15 days) followed by subcutaneous calcium‐heparin (5000 IU every 12 h for at least 2 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium‐heparin (5000 IU every 12 h for at least 2 weeks) started immediately
Number of subjects: 30